Cofactor said that current methods used to predict patient responses to ICIs like measuring PD-L1 combined positive score (CPS) and tumour mutational burden (TMB) are not effective. Both scores ...

David B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, ...

or oesophageal adenocarcinoma tumours that express PD-L1 with a combined positive score (CPS) of 5 or more. The decision extends the range of patients with these forms of gastro-oesophageal cancer ...

Among patients with a PD-L1 combined positive score (CPS) of at least 5, those in the Opdivo group (75 patients) achieved a median OS of 15.5 months versus 9.6 months for patients in the chemotherapy ...

Among patients with advanced gastric and GEJ cancer, or esophageal adenocarcinoma, treatment with first-line Opdivo and chemo demonstrated deep responses.

Data as of the 31 October 2024 cut-off date in evaluable 1L HNSCC patients (N=31) whose tumours express PD-L1 below 1 (Combined Positive Score [CPS] 1) and who typically do not respond well to ...

Nivolumab plus chemotherapy improved long-term survival in Chinese patients with advanced gastric, GEJ, or esophageal cancer.